| ID | 118993 |
| 著者 |
Yamashita, H
Kanaiso Hospital
板東, 浩
Kanaiso Hospital|Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association
KAKEN研究者をさがす
Kato, Y
Kanaiso Hospital
Ogura, K
Kanaiso Hospital
Kato, Y
Kanaiso Hospital
Sueki, E
Kanaiso Hospital
|
| キーワード | Semaglutide (Rybelsus)
Gastrointestinal adverse events (GIAEs)
Glucagon-like-peptide 1 receptor agonist (GLP1-RA)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Semaglutide Treatment Effect in People with Obesity (STEP)
Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: As glucagon-like-peptide 1 receptor agonist (GLP1-RA), oral semaglutide (Rybelsus) has been latest topic.
Case presentation: Patient is 72-year-old male with T2D, obesity, fatty liver and hypertension. He showed BMI 32.4 kg/m2 and HbA1c 8.1% in Nov 2021. Results: He started Rybelsus 3-7mg/day, and HbA1c and weight decreased for 8.1% to 7.0% and 92kg to 86.5kg with ALT/GGT improvement without gastrointestinal adverse events (GIAEs). Discussion: This case has arteriosclerotic cardiovascular disease (ASCVD). From cardiovascular outcome trials (CVOTs), semaglutide group revealed lower odd ratio (OR) for less CV death, as 0.47 of exenatide, 0.46 of dulaglutide and 0.43 of lixisenatide. |
| 掲載誌名 |
SunText Review of Medical & Clinical Research
|
| ISSN | 27664813
|
| 出版者 | SunText Reviews
|
| 巻 | 3
|
| 号 | 3
|
| 開始ページ | 161
|
| 発行日 | 2022-07-31
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
